-
Cubist Pharmaceuticals LLC v. Crane Pharmaceuticals LLC DC CAFC
- 1:16-cv-00072
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 02/10/2016
- Closed: 03/11/2016
- Latest Docket Entry: 05/24/2016
- PACER
- Docket updated daily
1
Plaintiff
1
Defendant
1
Accused
Product
4
Patents-in-Suit
31
Days in
Litigation
-
Cubist Pharmaceuticals LLC v. Crane Pharmaceuticals LLC DC CAFC
- 1:16-cv-00072
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 02/10/2016
- Closed: 03/11/2016
- Latest Docket Entry: 05/24/2016
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
91 |
The method of claim 85 wherein the composition is daptomycin that is essentially free of each of impurities 1 to 14 defined by peaks 1-14 shown in <figref idref="DRAWINGS">FIG. 12</figref>.
|
Invalid
Entry 8 |
98 |
The composition of claim 97, wherein the size selection technique is ultrafiltration or size exclusion chromatography.
|
Invalid
Entry 8 |
187 |
The composition of claim 183, wherein the daptomycin composition is at least or about 97% pure.
|
Invalid
Entry 8 |
Claim | Outcome |
---|---|
All challenged claims |
Invalid
Entry 8 |
Claim # | Claim Text | Outcome |
---|---|---|
23 |
The pharmaceutical composition of claim 22, wherein the daptomycin is obtained from the daptomycin aggregate by a method comprising the steps of a) filtering the daptomycin aggregate under conditions in which the daptomycin aggregate is retained on
view more
|
Invalid
Entry 8 |
53 |
The composition of claim 52, wherein a) the composition is a lyophilized powder compatible with a pharmaceutically acceptable carrier for the treatment of an infection by a daily intravenous dose of 1 to 12 mg/kg of the daptomycin in a reconstituted
view more
|
Invalid
Entry 8 |